PMOS Symptoms: What Each One Is Actually Telling You

The name changed in 2026. The symptoms did not.

In May 2026, a consensus of 56 academic, clinical and patient organisations renamed polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome — PMOS — in The Lancet. The consortium ran global surveys answered by 14,360 people with the condition and health professionals across every world region before landing on the term.

The reason is the point of this article. The old name aimed at the ovaries, and the ovaries are the smallest part of what you feel. The consensus paper says the term PCOS was inaccurate: it implies pathological cysts, and it obscures the endocrine and metabolic features that produce most of the day-to-day symptom load.

Nothing about the biology, the diagnostic criteria or the treatments changed. Only the label did. If you want the detail of that transition, PCOS is now PMOS covers it. This page uses both terms, because your medical notes and your search results still will.

The condition affects roughly one in eight women.

Why the symptoms cluster the way they do

Two engines drive almost everything on the list below, and they feed each other.

Androgen excess. Higher circulating testosterone acts on hair follicles and oil glands. Terminal hair grows where it is androgen-sensitive — jaw, chin, upper lip, chest, abdomen. Scalp hair at the crown thins for the same reason. Follicles in the ovary stall before one becomes dominant, so ovulation becomes irregular or stops.

Insulin resistance. A 2016 meta-analysis of gold-standard euglycaemic–hyperinsulinaemic clamp studies — the most precise way to measure insulin sensitivity — found insulin sensitivity 27% lower in women with PCOS than in controls (99% CI ±6%), and that this reduction was independent of BMI. A higher BMI made it worse by a further 15%, but it did not create it.

That single finding explains a lot of the frustration. Higher insulin pushes the ovary to make more androgen and lowers sex hormone-binding globulin, which frees up more testosterone to act on tissue. The same review found low SHBG tracked with lower insulin sensitivity, unconfounded by BMI.

The symptom list, and what each one means

Symptom	What is driving it	What the guideline does with it
Irregular or absent periods	Follicles stall; no dominant follicle, no ovulation	A diagnostic criterion. Defined by time since menarche
Hirsutism (coarse hair on face, chest, abdomen)	Androgen action on sensitive follicles	Hirsutism alone is predictive of biochemical androgen excess and of the syndrome in adults
Female-pattern hair loss	Androgen action at the crown	In isolation, a relatively weak predictor of androgen excess
Acne, especially jawline and cystic	Androgen-driven sebum production	In isolation, also a relatively weak predictor
Polycystic ovarian morphology on scan / high AMH	Accumulated immature follicles — not cysts	Either ultrasound or AMH may define it in adults. Not both. Not in adolescents
Raised glucose, raised fasting insulin	Intrinsic insulin resistance	75 g oral glucose tolerance test at diagnosis, regardless of BMI; repeat every 1–3 years
Anxiety and low mood	Multifactorial; not explained by body size alone	Screen every adult and adolescent, with regionally validated tools
Snoring plus waking unrefreshed, daytime sleepiness or fatigue	Obstructive sleep apnoea, more common in PMOS	Assess for these symptoms; if present, screen with a validated tool
Difficulty conceiving	Absent or unpredictable ovulation	Managed; the guideline emphasises cheaper and safer fertility options first

Which symptoms actually count toward a diagnosis

Three features are diagnostic. Most of the rest are consequences or associations, and having them does not, on its own, mean you have PMOS.

The guideline defines irregular cycles by how long it has been since your first period: 1 to under 3 years post-menarche, cycles shorter than 21 or longer than 45 days; 3 years post-menarche to perimenopause, cycles shorter than 21 or longer than 35 days, or fewer than 8 cycles a year. The first year after menarche is expected to be irregular and is not counted.

The ovarian criterion is where most confusion lives. In the population studies pooled by a 2016 meta-analysis, polycystic ovarian morphology appeared in 28% of women (95% CI 22–35%) — while only 6–10% met full diagnostic criteria depending on which definition was applied. A scan finding by itself is common and is not the syndrome.

The full criteria and the order tests should be run in are in the PMOS diagnosis criteria.

The symptoms most often left out of the conversation

The 2023 international guideline explicitly strengthened recognition of the “broader features” — metabolic risk factors, cardiovascular risk, sleep apnoea, and what it calls a very high prevalence of psychological features. Three years before the rename, the guideline had already widened the picture. The new name simply caught up with it.

Mood. A 2017 systematic review and meta-analysis of 30 cross-sectional studies found increased odds of moderate-to-severe depressive symptoms (OR 4.18, 95% CI 2.68–6.52) and of moderate-to-severe anxiety symptoms (OR 6.55, 95% CI 2.87–14.93). When groups were matched on BMI the association held — depressive symptoms OR 3.25, anxiety OR 6.30. Because every included study was cross-sectional, this shows association, not that PMOS caused the symptoms.

Sleep. If you snore and wake unrefreshed, that combination is worth naming out loud at your appointment. It is a specific screening trigger in the guideline, and it is routinely missed.

Glycaemic status. The guideline calls the 75 g oral glucose tolerance test the most accurate assessment in PMOS regardless of BMI — so a normal weight is not a reason to skip it.

What is not a PMOS symptom

Plenty of things get pinned on PMOS that the evidence does not support, and believing them costs you the investigation that would have found the real cause.

• Ovarian pain. The follicles seen on a scan are immature eggs, not cysts, and they do not hurt. Persistent pelvic pain needs its own workup — endometriosis and true ovarian cysts are separate conditions that can sit alongside PMOS.
• Voice deepening or clitoral enlargement. These are signs of much higher androgen levels than PMOS typically produces and point toward other diagnoses. They get investigated, not managed.
• Any single symptom on its own. Irregular periods alone have many causes — thyroid disease, raised prolactin, hypothalamic amenorrhoea, perimenopause. A diagnosis needs two of the three features and requires those other causes to be excluded first.
• Every difficult symptom you have. Fatigue, bloating and brain fog are real, common, and non-specific. They are not diagnostic of PMOS, and attributing them to it by default is how coeliac disease, anaemia and hypothyroidism get missed for years.

Does the symptom picture differ by phenotype?

Yes — by definition. Because a diagnosis needs two of three features, four combinations exist, and which two you have determines what you experience. Someone with irregular cycles and a polycystic-morphology scan but no androgen excess will not have the skin and hair symptoms at all. Someone with androgen excess and regular cycles may have nothing but hirsutism and still meet criteria.

What the evidence does not settle is whether one combination carries meaningfully more metabolic or cardiovascular risk than another. The 2023 recommendations do not stratify risk that way. Treat claims that rank the phenotypes by severity as unproven.

Your next step

Track two things for two cycles: the first day of each bleed, and the three symptoms that bother you most, scored 0–3 daily. Add the two sleep questions — do you snore, and do you wake unrefreshed. That single page does more in a ten-minute appointment than a list of worries, because it turns “my periods are all over the place” into a cycle length a clinician can act on.

Then work through the symptoms you actually have, one at a time. The rest of the symptoms section is organised that way.